Tilray, Inc. (NASDAQ:TLRY) traded at $7.32 at last check on Tuesday, Jun 30, making a downturn move of -4.99% on its previous day’s price.
Looking at the stock we see that its previous close was $7.71 with the day’s price range being $7.25 – 7.74. In terms of its 52-week price range, TLRY has a high of $49.49 and a low of $2.43. The company’s stock has gained about -21.73% over that past 30 days.
There have been no upward or downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the TLRY stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 100% Sell. Long term indicators on average place the stock in the category of 100% Sell.
Based on estimates by 16 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 13 have rated the Tilray, Inc. (TLRY) stock as a Hold, while 2 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas 1 suggests the stock as a Sell. The stock has an overall rating of Hold and investors could take advantage and scoop up stock of the company.
Let’s briefly compare Tilray, (TLRY) stock to its peers. We find that today’s price change of -4.99% and -83.44% over the past 12 months for TLRY competes that of Zoetis Inc Cl A (ZTS), which has seen its stock price rise 2% in the latest trading session and is +16.29% over the last one year. Another of its peers Takeda Pharmaceutical Co. Ltd (TAK) has dropped -1.91% today, and is +2.32% up over the past year, while Grifols S.A. (GRFS) is also down -4.99% yet its price remains in the red at -83.44% over the same period. Zoetis has a P/E ratio of 39.26 compared to Tilray,’s 0 and Takeda’s 22.32. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.04% and 0.46%, respectively, in early deals.